FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Chengdu Kanghong's KH815 enters human testing this month.
AACR approaches, along with ASCO abstract titles.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
First-in-human study listings include EOS-215 and RO7673396.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.